



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Review Article

A Comparative Study of Herbal Vs Conventional Therapies in Dysmenorrhoea Management

Harshada Dhak, Prerana Vairag*, Dr. Sonali Uppalwar

Ideal Institute of Pharmacy, Posheri, Wada, Mumbai University.

ARTICLE INFO

Published: 18 Nov 2025

Keywords:

Dysmenorrhoea, herbal therapy, conventional medicine, pain management, menstrual health, NSAIDs

DOI:

10.5281/zenodo.17637625

ABSTRACT

Dysmenorrhoea, often referred to as painful menstruation, is a prevalent gynecological issue that considerably impacts women's quality of life, productivity, and emotional health. Traditional treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs) and hormonal contraceptives are the primary options; however, their prolonged use is frequently linked to negative effects including gastrointestinal issues, hormonal imbalances, and pain recurrence. In recent years, herbal treatments have garnered increasing interest as natural and safer alternatives for alleviating menstrual pain. This comparative study seeks to assess the effectiveness, safety, and patient satisfaction of herbal remedies in contrast to conventional treatments for primary dysmenorrhoea. A thorough review of clinical trials and observational studies was performed utilizing databases such as PubMed, Scopus, and Google Scholar, concentrating on outcomes like pain alleviation, duration of relief, side effects, and overall quality of life. Herbal remedies such as *Zingiber officinale* (ginger), *Cinnamomum zeylanicum* (cinnamon), and *Foeniculum vulgare* (fennel) were evaluated against conventional medications like ibuprofen and mefenamic acid. The findings indicated that herbal therapies offered comparable or superior pain relief with minimal side effects, enhanced patient tolerance, and improved adherence to treatment. In contrast, conventional medications provided quicker relief but were associated with a higher incidence of adverse reactions and increased recurrence rates. In summary, the results imply that herbal therapies represent a promising, effective, and safer option for managing dysmenorrhoea, fostering holistic well-being and sustainable menstrual health.

INTRODUCTION

Dysmenorrhoea:

Lower abdominal and pelvic pain that happens during menstruation without any obvious pelvic disease is referred to as primary dysmenorrhea. About 50–90% of women who are of reproductive

***Corresponding Author:** Prerana Vairag

Address: Ideal Institute of Pharmacy, Posheri, Wada, Mumbai University.

Email ✉: preranavairag15@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



age are impacted. Most women with primary dysmenorrhea reported feeling less active at work or in school, which can result in both socioeconomic loss and a decline in quality of life.[1]

Types of dysmenorrhoea:

It is classified as primary dysmenorrhea, which occurs in the absence of pelvic disease and is frequently associated with elevated levels of prostaglandins, or secondary dysmenorrhea, which arises from conditions such as endometriosis or fibroids.[2]

1. **Primary dysmenorrhoea:** Prostaglandins (PGs) are believed to be the primary factor behind dysmenorrhea.[3,4] Elevated levels of PGs have been observed in the menstrual fluid and endometrial tissue of women experiencing dysmenorrhea.[5] The shedding of the endometrium begins as hormone levels decline during the menstrual cycle. At the onset of menstruation, when the endometrial cells discharge PGs, is when endometrial shedding occurs. PGs induce contractions in the uterus, and the severity of cramps is directly related to the quantity of PGs released.[5,6] These uterine contractions can result in tissue hypoxia and ischemia, leading to pain and sometimes accompanying symptoms like nausea and diarrhea.[19]

2. **Secondary dysmenorrhoea:** Secondary dysmenorrhea refers to menstrual discomfort arising from an underlying condition, disorder, or structural issue, either within or outside the uterus.[7] This condition can impact women at any point after the onset of menstruation. It may emerge as a new symptom for women in their 30s or 40s. Secondary dysmenorrhea can present with varying levels of pain, and may also include additional symptoms such as pain during intercourse, heavy menstrual bleeding, bleeding between periods, and bleeding after intercourse. There are several common contributors to secondary dysmenorrhea, including endometriosis, a large cesarean scar niche, fibroids, adenomyosis, endometrial polyps, interstitial cystitis, pelvic inflammatory disease, and potentially the use of an intrauterine device.[3,20, 8] Up to 29% of women experiencing dysmenorrhea might be affected by endometriosis. In cases of dysmenorrhea that do not respond to NSAIDs, around 35% of patients may have endometriosis.[9] Adenomyosis is a prevalent condition that often contributes to secondary dysmenorrhea. As many as 3.8% of younger women may have abnormalities in their reproductive tract, and both obstructive and non-obstructive anomalies can be linked to secondary dysmenorrhea.




Figure no:1 Types of dysmenorrhoea [10]

Currently, pharmacological treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs) and hormonal contraceptives, serve as the primary approach for managing PD. While NSAIDs provide immediate pain relief, they do not demonstrate long-term effectiveness. Furthermore, prolonged use of NSAIDs may elevate the risk of adverse effects, particularly affecting the digestive and central nervous systems, leading to issues such as indigestion, headaches, drowsiness, and poor treatment adherence.[11-13] Hormonal contraceptives are frequently utilized in PD management as well, but they are often associated with side effects such as weight gain, breast discomfort, menstrual irregularities, and other negative reactions.[14,15] Moreover, it has been reported that the frequent use of these medications results in a failure rate ranging from 20% to 25%. Consequently, an increasing number of individuals are turning their attention to complementary and alternative therapies for PD.[16]

The approach to managing dysmenorrhea primarily Involves two methods: pharmacological and non-pharmacological treatments. Non-steroidal anti-inflammatory drugs

(NSAIDs) like ibuprofen, naproxen, and mefenamic acid are commonly prescribed for women with primary dysmenorrhea (PD). Other medications, including oral contraceptive pills (OCPs), antispasmodics, and acetaminophen, are also utilized. Nevertheless, prolonged use of NSAIDs and OCPs can result in negative side effects, such as damage to the gastrointestinal tract lining, which may cause GI discomfort. The side effects linked to these treatments have prompted women to explore complementary and alternative medicine options, including various herbs, dietary changes, or physical activity. Numerous healthcare practitioners around the globe have turned to medicinal plants like fennel, ginger, and cinnamon due to their pain-relieving properties. In addition, applying local heat, engaging in exercise, ensuring adequate rest, and limiting fatty foods have demonstrated positive effects in managing PD, with no significant negative effects recorded. While pharmacological treatments can have adverse effects, they are still regarded as the most effective and dependable options for treating dysmenorrhea.[17]

According to traditional Chinese medicine, dysmenorrhea is attributed to the stagnation of

cold and dampness in the uterine collaterals, which can be caused by consuming cold beverages or being exposed to rain and wet conditions. The invasion of cold leads to blood coagulation, resulting in obstructed uterine collaterals, known as stagnation, which ultimately causes pain. Therefore, the treatment for dysmenorrhea should concentrate on warming the meridians, dispelling cold, and alleviating dampness. Cinnamon (*Cinnamomum zeylanicum*), fennel (*Foeniculum vulgare*), and ginger (*Zingiber officinale*) are widely recognized natural products that help warm meridians, dispel cold, and eliminate dampness. Cinnamon, a fragrant spice, has been utilized to address various inflammatory conditions and

chronic illnesses, including menstrual discomfort, arthritis, diabetes, and Alzheimer's disease. Fennel, noted for its contrastimulant and analgesic properties, is regarded as an effective herbal remedy for dysmenorrhea, despite its less-than-pleasant flavor. Ginger is beneficial for alleviating discomfort linked to dysmenorrhea, rheumatoid arthritis, osteoarthritis, and gastrointestinal issues such as diarrhea, nausea, and vomiting. Some research has also indicated that ginger can aid in relieving pain for women experiencing dysmenorrhea. However, there has yet to be a comprehensive effort to compile the existing evidence that supports the effectiveness of these three herbs in treating primary dysmenorrhea.[18]



Figure no.2 Dysmenorrhoea symptoms [21]

Pathophysiology Of Dysmenorrhoea:

The exact mechanisms underlying primary dysmenorrhea remain unclear. However, it is thought that the primary cause is linked to the excessive production of prostaglandins (PGs) by the inner lining of the uterus. These prostaglandins

induce pain by amplifying uterine contractions and increasing pressure within the uterus. Additionally, factors such as reduced blood flow to the uterus, ischemia, lack of oxygen, and byproducts from anaerobic metabolism may contribute to the experience of pain.[20]The elevated levels of collagenases, inflammatory

cytokines, and matrix metalloproteinases in the endometrium are related to lower levels of progesterone and estradiol during menstruation. The resulting disintegration of endometrial tissue releases phospholipids, which are then transformed into arachidonic acid. This

arachidonic acid is subsequently converted into prostacyclins, prostaglandins, and thromboxane-2a through the action of cyclooxygenase.[9]The substances PG F2 alpha (PGF-2 α) and PG E2 (PGE2) enhance uterine tone and induce strong contractions of the uterus.[22]




Figure no:3. Pathophysiology of dysmenorrhoea [26]

During menstruation, the levels of COX-2, a type of cyclooxygenase, are notably elevated, which has led to the use of NSAIDs for treatment, as mentioned below. [9]Vasopressin has also been associated with primary dysmenorrhea, as it boosts uterine contractility and can lead to ischemic pain due to its vasoconstrictive properties.[23][25]Additionally, levels of leukotrienes C4 and D4 are increased in individuals with dysmenorrhea and seem to correlate with an upsurge in uterine contractions.[20]Moreover, uterine contractility is most pronounced in the first two days of menstruation, aligning with the peak frequency and intensity of dysmenorrhea during this time.[24]

Endometriosis and adenomyosis represent the leading causes of secondary dysmenorrhea among premenopausal women.[24]

Primary Methods:

1. Study design

In order to examine the efficacy and safety of herbal medications given for a minimum of ten days this study divided individuals into three groups:

- Group 1 (decoction only) received only herbal decoction;
- Group 2 (combination group) received herbal decoction together with additional Korean

medicine treatments (such as acupuncture, moxibustion, and chuna).

- **Group 3: Non-decoction Group:** Herbal compositions that do not use decoction, such as pills, extracts, or granules. Based on patient symptoms, preferences, and clinical judgment, physicians assigned patients to groups. There was not an untreated control group; all individuals received treatment with Korean medicine.[2]

2. Intervention

Depending on group assignment, participants will receive oral DJS, GSS, or a placebo three times daily for two menstrual cycles. Each person will have a different intervention duration, which might be anything from 42 to 80 days. As a result, for each menstrual cycle, the participants will receive enough medication for 43 days of administration, taking into account a maximum of 40 days and window visit (three days). The remaining unused medication will be returned in order to increase participant adherence to the intervention guidelines. Alternative therapies for dysmenorrhea, including low frequency therapy, moxibustion, acupuncture, and infrared radiation, will not be allowed. Oral contraceptives, psychiatric medications, and herbal remedies will not be allowed, although participants may self-administer medications that are not listed in the inclusion or exclusion criteria. The Consolidated Standards of Reporting Trials (CONSORT) Extension for Chinese Herbal Medicine Formulas' interventions item will be followed in the description of the interventions.[27]

3. Participant

Those who received herbal treatment for dysmenorrhea, gave their informed consent, consented to the use of their data, comprehended the study, and filled out the surveys were eligible

to participate. Serious comorbidities (such as neurological, mental, cardiovascular, or renal problems), pregnancy planning, or involvement in other clinical studies were among the exclusion criteria. Participants were drawn from general clinics that provide non-insurance-based, out-of-pocket treatments as well as clinics taking part in the nationwide pilot study for insurance coverage of herbal decoctions. Of the 135 participants who finished the trial, 72 (53.33%) were uninsured general patients, and 63 (46.67%) were enrolled through the pilot insurance program.[2]

4. Outcome measures

Primary outcome:

The duration of menstrual pain, the amount of analgesics taken, and the mean change in dysmenorrhea intensity (as determined by a numerical rating scale, or NRS) were the main outcomes. At every treatment cycle, including assessments following the first and second menstruations, outcomes were evaluated. Although telephone or online surveys were used with participants' permission, the majority of assessments were carried out in person.[2]

If the average VAS at the conclusion of the intervention (V4) differs by more than 15 mm from the baseline (V2), the intervention will be deemed successful. Endometriosis, a representative condition that causes secondary dysmenorrhea, has a minimal clinically meaningful difference (MCID) of 10 mm using VAS,[28] and Primary dysmenorrhea has improved to a slightly greater extent than secondary dysmenorrhea.[29]

Secondary outcome:

Adverse events, pleasure, and self-rated effectiveness were secondary outcomes. A 4-point



scale was used to measure clinical improvement; lower values denoted more effectiveness (1 being a significant improvement and 4 being no impact). Herbal medicine and total Korean medicine treatment satisfaction were assessed separately using a 7-point rating system. Overall satisfaction was correlated with the type of intervention, although preferences for formulation type were reflected in herbal medication satisfaction. In order to evaluate the safety of herbal medicines, doctors tracked adverse events during the trial, documenting any symptoms, reactions, or treatments at each visit.[2]

5. Statistical analysis

ANOVA and chi-square tests were used to evaluate the demographic data, and the results were displayed as means $\pm$ SD or frequencies. Within-group changes were evaluated using paired t-tests, while between-group comparisons were evaluated using the Kruskal-Wallis test. Mann-Whitney U tests were performed post hoc when significant. A p-value of less than 0.05 was deemed significant. Missing values were imputed using the mean for continuous data and the simple for categorical data. The software SPSS 23.0 was used for the analyses.[2]

Conventional Treatment:

The primary goal of treatment for primary dysmenorrhea (PD) is to provide effective pain relief for individuals experiencing dysmenorrhea, allowing them to continue their normal activities, enhance their quality of life (QOL), and reduce absenteeism related to work or academic responsibilities.[30,31] Both pharmacological and non-pharmacological alternative therapies can serve as viable options for managing PD.[32] The initial recommended treatments for PD include nonsteroidal anti-inflammatory drugs (NSAIDs) and hormonal contraceptives, as they reduce the

production of prostaglandins, which are directly linked to menstrual pain and its accompanying systemic symptoms.[30,31,33,34]

Pharmacological Therapies:

- 1) Nonsteroidal anti-inflammatory drugs : Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective and economical pain relievers and anti-inflammatory medications, frequently utilized for treating primary dysmenorrhea (PD) [30,35,36,37,11] They are deemed essential in the treatment of dysmenorrhea as they block the activity of cyclooxygenase, which subsequently reduces the production of prostaglandins [38]. As a result, NSAIDs are advised as the initial treatment option for women who prefer analgesics or in cases where contraceptives are not suitable [33,30,23].

The timing of NSAID administration is a predictor of its effectiveness. To achieve optimal treatment efficacy and safety, NSAIDs ought to be started 1 to 2 days prior to the anticipated onset of menses, taken with meals to mitigate adverse gastrointestinal effects, following a consistent dosing schedule, and maintained throughout the initial 2 to 3 days of bleeding.[30,31,39] It has been determined that the administration of NSAIDs prior to the induction of the COX-2 cascade leads to a total inhibition of prostaglandin synthesis. Therefore, postponing the consumption of NSAIDs results in a gradual or partial suppression.[39] If a patient does not show improvement with a specific NSAID, replacing it with one from a different class presents an alternative treatment option [33,23]. While the majority of females tend to respond positively to NSAID therapy, it has been noted that 18% do not respond sufficiently to these medications [36]. For females who do not respond to NSAIDs, transitioning to hormone-based treatments and/or

non-pharmacological therapies may be considered.[36]

primarily for mild to moderate dysmenorrheic pain.

2) Hormonal contraceptives: Hormonal contraceptives are regarded as the primary treatment option for managing dysmenorrhea, except in cases where they are contraindicated. They are typically advised for females experiencing dysmenorrhea who require contraception, for whom the use of contraceptives is deemed appropriate, or for individuals who are unable to tolerate or do not respond to NSAIDs [33,30,31].

Hormonal contraceptives have been demonstrated to inhibit ovulation and the proliferation of the endometrium, thereby preventing the synthesis of prostaglandins [40]. The hormonal treatments employed in the management of PD encompass options such as combined oral contraceptives (COC), transdermal contraceptive patches or vaginal rings, a levonorgestrel intrauterine device, and subcutaneous depot medroxyprogesterone acetate, proven to be effective in managing PD[41].

3) Acetaminophen (Paracetamol): Acetaminophen serves as a suitable pharmacological analgesic for patients experiencing dysmenorrhea who prefer not to use hormonal contraceptives and are unable to tolerate NSAIDs due to gastrointestinal issues [42]. Due to its limited COX inhibitory effect, it decreases the production of prostaglandins [43] and is regarded as a safe analgesic with manageable gastrointestinal side effects [43]. However, various studies examining the effectiveness of different treatments for the management of primary dysmenorrhea have shown that acetaminophen is less effective than NSAIDs and hormonal contraceptives [44,11,45]. Therefore, it is recommended

Non- Pharmacological Interventions:

The application of non-pharmacological interventions is prevalent among females experiencing dysmenorrhea. A recent meta-analysis involving 12,526 dysmenorrheic females indicated that 51.8% utilized various non-pharmacological strategies to alleviate their menstrual discomfort [47]. To address dysmenorrhea, numerous non-pharmacological interventions have been suggested, which can be used independently as an alternative treatment or in conjunction with NSAIDs or COCs as a supplementary therapy [38,33,30,31]. These interventions were proposed to alleviate menstrual pain through various mechanisms, such as enhancing pelvic blood flow, suppressing uterine contractions, promoting the release of endorphins and serotonin, and modifying the capacity to receive and interpret pain signals [50,47,51,52].

The application of heating pads and consistent physical activity, whether as a substitute or an adjunct therapy, ought to be promoted due to their demonstrated effectiveness, rare adverse effects, and affordability [30,31]. However, there is a lack of adequate evidence regarding the effectiveness of dietary supplements (including vitamins B, D, and E, as well as omega-3 fatty acids), acupuncture, yoga, massage, and herbal treatments in the treatment of PD [47,33,30,31,53].

Its analgesic effect is facilitated through two distinct mechanisms. The first mechanism entails raising the sensory threshold for uterine pain by relaying a sequence of afferent electrical signals through large-diameter sensory fibers, which leads to a diminished perception of pain associated with uterine hypercontractility during menstruation. In contrast, the second mechanism pertains to the

stimulation of endorphin release by peripheral nerves, which contributes to pain relief [54-56].

Surgical Interventions:

In exceptional cases, surgical procedures have been suggested for individuals suffering from severe dysmenorrhea who do not respond to standard treatment options. These surgical procedures encompass laparoscopic uterosacral nerve ablation (LUNA), presacral neurectomy (PSN), and hysterectomy [57,30,31]. Both LUNA

and PSN entail the disruption of cervical sensory pain fibers by severing afferent nerve fibers located in the uterosacral ligaments or pelvis. Nevertheless, due to a lack of sufficient evidence to validate the effectiveness and safety of these procedures, they are unlikely to be endorsed for the management of PD [57,58]. Furthermore, hysterectomy is regarded as a last resort in cases of severe refractory dysmenorrhea, but it should be avoided in adolescents, young women, and those who wish to become pregnant [59].




Figure no:4 Dysmenorrhoea Treatments [60]

Herbal Remedies:

1. **Ginger:** Certain individuals hold the belief that ginger may alleviate menstrual cramps by diminishing inflammation and lowering the production of pain-inducing prostaglandins. A review conducted in 2015, which analyzed seven studies, found suggestive evidence supporting the efficacy of 750–2,000 milligrams (mg) of ginger powder for dysmenorrhea during the initial three to four days of the menstrual cycle.[61] Nevertheless, a Cochrane review of the studies concluded that, although some studies indicated benefits

while others did not, the overall quality of the studies reviewed was inadequate.[62]



Figure no:5 Ginger [71]

2. **Fennel:** This herb possesses a taste reminiscent of licorice and a texture similar to that of celery. It contains a compound known as anethole, which some believe may alleviate spasms. A review conducted in 2020 indicated that fennel was able to reduce pain intensity as effectively as traditional drug therapy and more effectively than a placebo.[63] All components of the fennel plant are consumable. The bulb can be incorporated raw into salads or cooked to enhance the flavor of soups. The fronds and dried fennel seeds can be utilized as a spice. Fennel extract is obtainable in both oil and capsule forms.



Figure no:6 Fennel [72]

3. **Chamomile:** The anti-inflammatory and anti-spasmodic characteristics of chamomile seem to assist in alleviating menstrual cramps. Research indicates that chamomile can diminish the pain associated with cramps more effectively than a placebo. Furthermore, chamomile has been shown to ease mood-related symptoms linked to premenstrual syndrome (PMS). A review from 2019, which examined eight studies, noted that chamomile tea was the most frequently administered form to study participants, although chamomile extract also appears to be effective in relieving menstrual cramps.[64]



Figure no:7 Chamomile [73]

4. **Pycnogenol:** This herbal extract is derived from the bark of the French maritime pine (*Pinus pinaster*). A small study conducted in 2014 with 24 participants indicated that among women using oral birth control who took Pycnogenol for three months, 27% experienced relief from pain, in contrast to 0% in the placebo group.[65] However, a Cochrane review published in 2020 found no evidence supporting the efficacy of Pycnogenol in alleviating menstrual cramps.[66] Pycnogenol is offered as a dietary supplement in capsule form and is deemed safe for consumption in doses ranging from 50 mg to 450 mg daily for a duration of up to one year.



Figure no:8 Pycnogenol [74]

5. **Cinnamon:** This spice is believed to alleviate menstrual cramps by mitigating inflammation and pain associated with prostaglandins. A review from 2020 revealed that cinnamon, in conjunction with fennel and ginger,

significantly reduced pain intensity, and cinnamon also contributed to a decrease in the duration of pain.[18] Additionally, two other studies demonstrated that the administration of cinnamon capsules (450 mg three times daily and 1,000 mg once daily) led to a reduction in pain intensity when compared to a placebo.[67,68]



Figure no:9 Cinnamon [75]

6. **Peppermint:** The active ingredient in peppermint, menthol, exhibits an analgesic (pain-relieving) effect. A study conducted in 2016 involving 127 participants demonstrated that peppermint extract in capsule form was equally effective as mefenamic acid (a type of NSAID) in alleviating pain intensity and duration, while presenting a lower risk of side effects.[69] As a recognized muscle relaxant, peppermint oil may also possess the ability to alleviate menstrual cramps; however, no studies have yet explored the efficacy of peppermint for this particular application. [70]It may be necessary to utilize a more concentrated form, such as peppermint extract, to effectively relieve menstrual cramps.



Figure no: 10 Peppermint [76]

Differential Diagnosis:

The differential diagnosis of dysmenorrhea encompasses a wide range of conditions. It can be divided into gynecological and non-gynecological categories: [77]

A. Gynecological Conditions

- Endometriosis
- Obstruction of the reproductive tract: including imperforate hymen, transverse vaginal septum, vaginal agenesis, OHVIRA syndrome (characterized by uterus didelphys with obstructed hemivagina and ipsilateral renal agenesis), and cervical stenosis
- Functional and nonfunctional adnexal cysts
- Adnexal torsion (typically, this does not manifest with cyclic pain during menstruation)
- Adenomyosis-
- Pelvic inflammatory disease/sexually transmitted infections
- Endometrial polyps
- Asherman syndrome
- Ectopic pregnancy
- Chronic pelvic pain
- Membranous dysmenorrhea: a rare cause of colicky pain resulting from uterine contractions that lead to the shedding of the endometrium in a single piece, maintaining the shape of the uterus [78]

B. Non-Gynecological Conditions (gastrointestinal, urological, and musculoskeletal)

- Irritable bowel syndrome
- Urinary tract infections
- Interstitial cystitis
- Musculoskeletal factors: abdominal wall muscles, abdominal wall fascia, pelvic and hip muscles, sacroiliac joints, and lumbosacral muscles.

Pertinent Studies and Ongoing Trials:

Different phenotypes of dysmenorrhea probably exist; each associated with distinct underlying causes. The implementation of breakthrough pain management in treating dysmenorrhea, along with monitoring this in conjunction with menstrual pain, may prove beneficial in the future as relevant studies on NSAID-resistant treatments for dysmenorrhea develop.[9]

Prognosis:

An initial medical treatment procedure is initiated and maintained for a duration of 2 to 3 months prior to conducting a reassessment of the symptoms. Should there be an improvement in symptoms, yet they persist, an additional treatment method may be introduced. If there is little to no positive response observed, a modification of the treatment plan with the cessation of the initial approach might be proposed. Patients are to continue with the treatment for a further 3 months before undergoing another assessment. In the event that an adequate response is not achieved, an evaluation for a potential underlying cause of secondary dysmenorrhea may be commenced. Moreover, a comprehensive assessment of pelvic pain that includes contributions from physical therapy may also be taken into consideration.

Dysmenorrhea can considerably affect the daily lives of patients. This effect is evident in the levels of absenteeism from educational institutions or workplaces. Additionally, dysmenorrhea may restrict a patient's involvement in athletic activities or social gatherings. Moreover, there are emotional stressors linked to dysmenorrhea. In the United States, it is estimated that dysmenorrhea accounts for approximately 140 million hours of work lost annually, representing a public health issue with substantial economic consequences.[79]

The outlook for primary dysmenorrhea is typically favorable when recommended treatment options are utilized. Mild to moderate dysmenorrhea generally shows a positive response to NSAIDs. Although severe dysmenorrhea may also respond to NSAIDs, it might necessitate higher dosages or the use of combination/adjuvant therapies. In instances of persistent dysmenorrhea, it is essential to explore secondary causes. The prognosis for secondary dysmenorrhea is contingent upon the underlying etiology, type, location, and severity of the condition.

Complications:

The complications associated with primary dysmenorrhea can be characterized by the severity of the pain and its impact on the patient's overall well-being, as well as its interference with daily activities. Given that primary dysmenorrhea is not associated with any underlying pathology or disease, there are no further known complications.

Conversely, the complications of secondary dysmenorrhea differ based on the underlying cause. These complications may encompass infertility, pelvic organ prolapse, excessive bleeding, and anemia, among others.[24][80]

Deterrence And Patient Education:



A balanced and nutritious diet, along with consistent physical activity, can alleviate the intensity of dysmenorrhea.[81] It is crucial to inform and raise awareness among young individuals about the significance of maintaining a well-balanced diet to mitigate the discomfort associated with dysmenorrhea. Certain vitamins and healthy dietary changes have been linked to a decrease in menstrual pain.[82][83][84]

Engaging in regular exercise has proven to be beneficial in lessening dysmenorrhea. Physical activity serves as a non-specific pain reliever by enhancing pelvic blood flow and promoting the release of β -endorphins.

The main objective of treatment is to alleviate pain and enhance the quality of life for individuals experiencing dysmenorrhea. Medical and procedural interventions should be utilized judiciously to enable affected individuals to carry out their daily activities without significant interruptions to their education or employment. Patients are encouraged to consult their healthcare provider if dysmenorrheic symptoms become troublesome and are not adequately managed.

Enhancing Healthcare Team Outcomes:

In the management of dysmenorrhea, it is crucial to adopt a multifaceted approach that involves a diverse team of healthcare professionals to guarantee patient-centered care and achieve optimal outcomes. Healthcare experts, including physicians, advanced care practitioners, nurses, pharmacists, and pelvic physical therapists, must have a comprehensive skill set that encompasses a profound understanding of gynecological health and pain management.

The strategy of the interprofessional team should focus on evidence-based, personalized treatment plans that cater to the distinct needs and

preferences of each patient, while also adhering to ethical guidelines that uphold patient autonomy and informed consent. Patients ought to receive appropriate counseling regarding the treatment options available for dysmenorrhea, as well as the potential complications linked to secondary dysmenorrhea. The management of dysmenorrhea in a patient is contingent upon the severity of symptoms and the effectiveness of the treatment. The ultimate goal is to achieve improved outcomes with minimal disruption to daily activities.

Healthcare professionals are tasked with delivering compassionate and culturally aware care that enhances patient safety while reducing the risk of adverse effects or complications. Efficient interprofessional communication is essential to facilitate a smooth exchange of information and coordinated care, allowing the team to collaboratively customize treatments and interventions for each patient. By combining their expertise, strategies, ethical considerations, responsibilities, and communication efforts, the interprofessional team can improve patient-centered care, enhance outcomes, increase patient safety, and optimize team performance in the management of dysmenorrhea.[85]

Approaches To Treatment:

Alternative and conservative methods of care Following the initial evaluation, patients are frequently reassured that primary dysmenorrhea is a recognized disorder and that the disease is improbable. When patients show up early, the anomaly usually goes away over time. (After five years, prevalence drops from 72 to 67 percent in 19-year-olds, from 15 to 10 percent in those with daily activity limitations, and from 51 to 34 percent in work absenteeism.) Dysmenorrhea also usually gets better after giving delivery. One should not undervalue the therapeutic value of a patient's relationship with her physician. Patients



report feeling more relieved and satisfied with their care when their medical professionals communicate with them and involve them in decision-making. Exercise may alleviate dysmenorrhea, although observational investigations have yielded inconsistent results, and controlled trials have been limited and of low quality. There are plausible ways that exercise could be beneficial, and since it improves overall health and well-being, patients should be encouraged to engage in it. Although it is unknown if changing these factors can lessen symptoms, patients should be advised that smoking, obesity, stress, and alcohol usage are linked to more severe dysmenorrhea. The benefits of dietary supplements have not been demonstrated. However, since the intervention frequently has a large placebo effect, it is prudent to encourage women to use alternative or herbal therapies when there are strong cultural beliefs in them and where danger is improbable and the cost is not exorbitant. Numerous modest trials have shown the effectiveness of high-frequency transcutaneous electrical nerve stimulation (TENS), which is a good substitute for women who want to take less medications. According to current systematic reviews, there is inadequate evidence to support either acupuncture or behavioral therapy because most trials have small sample sizes and poor methodological quality.[86]

Prevention:

Dysmenorrhea has been treated in an outpatient setting using a variety of strategies, such as the following: Changing one's lifestyle seems to be beneficial. Given that smoking may increase the likelihood of dysmenorrhea, quitting should be urged [87, 89]. Although the exact mechanism is unclear, exercise has been demonstrated to reduce dysmenorrhea symptoms [88, 90]. Relaxation techniques and other behavioral therapies may be

useful in treating primary and secondary dysmenorrhea, according to a Cochrane review of five randomized controlled studies. [88] Relaxation exercise proved to be the most successful exercise strategy for reducing discomfort related to primary dysmenorrhea, according to a meta-analysis that looked at strength training, aerobic activity, yoga, combined exercise, relaxation exercise, and the Kegel maneuver. [91]

CONCLUSION:

The comparative examination of herbal and conventional treatments for dysmenorrhoea underscores the increasing significance of merging traditional knowledge with contemporary medicine. Although conventional therapies, including NSAIDs and hormonal treatments, deliver swift and effective pain relief, they frequently come with adverse effects and restricted long-term tolerance. Conversely, herbal solutions—such as *Zingiber officinale* (ginger), *Cinnamomum zeylanicum* (cinnamon), *Foeniculum vulgare* (fennel), and *Curcuma longa* (turmeric)—provide a safer, more comprehensive approach by addressing the root inflammatory and hormonal imbalances with minimal side effects.

In summary, herbal treatments not only relieve menstrual discomfort but also promote overall health and menstrual regularity, positioning them as a promising complementary or alternative option. Nevertheless, the necessity for standardized formulations, thorough clinical trials, and explicit dosage guidelines is essential to validate their efficacy and safety in comparison to conventional therapies. The future of managing dysmenorrhoea may indeed reside in an evidence-based fusion of herbal and conventional methods, ensuring effective, safe, and patient-centered care.



REFERENCES

- Ji, H. R., Park, K. S., Woo, H. L., Lee, M. J., Yoon, J. G., Lee, H. J., ... & Lee, J. M. (2020). Herbal medicine (Taohong Siwu Tang) for the treatment of primary dysmenorrhea: a systematic review and meta-analysis. *Explore*, 16(5), 297-303.
- Cho, S. I., Jung, H. J., Park, M., & Kim, D. I. (2025). Effectiveness and safety of herbal medicine on treatment of dysmenorrhea: An analysis of a multicenter, prospective observational study. *Integrative Medicine Research*, 101209.
- Proctor M, Farquhar C. Diagnosis and management of dysmenorrhoea. *BMJ*. 2006 May 13;332(7550):1134-8. [PMC free article] [PubMed]
- Lundström V, Gréen K, Svanborg K. Endogenous prostaglandins in dysmenorrhea and the effect of prostaglandin synthetase inhibitors (PGSI) on uterine contractility. *Acta Obstet Gynecol Scand Suppl*. 1979;87:51-6. [PubMed]
- Coco AS. Primary dysmenorrhea. *Am Fam Physician*. 1999 Aug;60(2):489-96. [PubMed]
- Ylikorkala O, Dawood MY. New concepts in dysmenorrhea. *Am J Obstet Gynecol*. 1978 Apr 01;130(7):833-47. [PubMed]
- Mrugacz G, Grygoruk C, Sieczyński P, Grusza M, Bołkun I, Pietrewicz P. [Etiopathogenesis of dysmenorrhea]. *Med Wieku Rozwoj*. 2013 Jan-Mar;17(1):85-9. [PubMed]
- Budny-Winska J, Pomorski M. Uterine niche after cesarean section: a review of diagnostic methods. *Ginekolog Pol*. 2021;92(10):726-730. [PubMed]
- Oladosu FA, Tu FF, Hellman KM. Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment. *Am J Obstet Gynecol*. 2018 Apr;218(4):390-400. [PMC free article] [PubMed]
- Figure no:1
<https://share.google/swVQ1GMSSY7Ulgedz>
- Marjoribanks J, Ayeleke RO, Farquhar C, et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. *Cochrane Database Syst Rev* 2015;(7):CD001751.
- Tziona P, Theodosios-Nobelos P, Rekka EA. Medicinal chemistry approaches of controlling gastrointestinal side effects of non-steroidal anti-inflammatory drugs. Endogenous protective mechanisms and drug design. *Med Chem* 2017;13:408–20.
- Abaraogu UO, Igwe SE, Tabansi-Ochiogu CS. Effectiveness of SP6 (Sanyinjiao) acupressure for relief of primary dysmenorrhea symptoms: a systematic review with meta and sensitivity analyses. *Complement Ther Clin Pract* 2016;25:92–105.
- Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. *Eur J Clin Pharmacol* 2008;64:233–52.
- Uysal G, Akkaya H, Cagli F, et al. A comparison of two different oral contraceptives in patients with severe primary dysmenorrhoea. *J Obstet Gynaecol* 2018;38:828–32.
- Zhai, F., Wang, D., Hua, Z., Jiang, Y., & Wang, D. (2019). A comparison of the efficacy and safety of complementary and alternative therapies for the primary dysmenorrhea: A network meta-analysis protocol. *Medicine*, 98(19), e15586.
- Tahir, A., Naseer, B., & Shafaq, F. (2025). Perception of university students about the use of painkillers, other remedies and lifestyle modifications for primary dysmenorrhea; a cross-sectional study at KEMU. *BMC Women's Health*, 25(1), 234.



18. Xu, Y., Yang, Q., & Wang, X. (2020). Efficacy of herbal medicine (cinnamon/fennel/ginger) for primary dysmenorrhea: a systematic review and meta-analysis of randomized controlled trials. *Journal of International Medical Research*, 48(6), 0300060520936179.
19. Kho KA, Shields JK. Diagnosis and Management of Primary Dysmenorrhea. *JAMA*. 2020 Jan 21;323(3):268-269. [PubMed]
20. Ferries-Rowe E, Corey E, Archer JS. Primary Dysmenorrhea: Diagnosis and Therapy. *Obstet Gynecol*. 2020 Nov;136(5):1047-1058. [PubMed]
21. Figure
no:2https://www.google.com/imgres?imgurl=https%3A%2F%2Fwww.jmchemsci.com%2Fdata%2Fjmcs%2Fcoversheet%2F101619066272.jpg&tbid=OHKFT8wJvibOEM&vet=1&imgrefurl=https%3A%2F%2Fwww.jmchemsci.com%2Farticle_129459.html&docid=G2zPmp4lZxIswM&w=422&h=413&hl=en-US&source=sh%2Fx%2Fim%2Fm1%2F4&ks=2d4f5d18935a050b&shem=isst
22. Word RA, Kamm KE, Casey ML. Contractile effects of prostaglandins, oxytocin, and endothelin-1 in human myometrium in vitro: refractoriness of myometrial tissue of pregnant women to prostaglandins E2 and F2 alpha. *J Clin Endocrinol Metab*. 1992 Oct;75(4):1027-32. [PubMed]
23. Ekström P, Akerlund M, Forsling M, Kindahl H, Laudanski T, Mrugacz G. Stimulation of vasopressin release in women with primary dysmenorrhoea and after oral contraceptive treatment—effect on uterine contractility. *Br J Obstet Gynaecol*. 1992 Aug;99(8):680-4. [PubMed]
24. Bernardi M, Lazzeri L, Perelli F, Reis FM, Petraglia F. Dysmenorrhea and related disorders. *F1000Res*. 2017;6:1645. [PMC free article] [PubMed]
25. French L. Dysmenorrhea. *Am Fam Physician*. 2005 Jan 15;71(2):285-91. [PubMed]
26. Figure
no:3.
<https://share.google/BVcV77FnnfdpY7s3x>
27. C.W. Cheng, T.X. Wu, H.C. Shang, et al. CONSORT extension for chinese herbal medicine formulas 2017: Recommendations, explanation, and elaboration.
28. C. Gerlinger, U. Schumacher, T. Faustmann, A. Colligs, H. Schmitz, C. Seitz. Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: Analyses of two placebo-controlled, randomized trials health qual Life Outcomes, 8 (2010), p. 138.
29. M.L. Proctor, C.M. Farquhar Dysmenorrhoea *BMJ Clin Evid*, 2007 (2007), p. 813.
30. Burnett M, Lemyre M. No. 345: primary dysmenorrhea consensus guideline. *J Obstet Gynaecol Can*. 2017;39:585–95. doi: 10.1016/j.jogc.2016.12.023. [DOI] [PubMed] [Google Scholar]
31. ACOG committee opinion no. 760: dysmenorrhea and endometriosis in the adolescent. *Obstet Gynecol*. 2018;132:e249–58. Doi: 10.1097/AOG.0000000000002978. [DOI] [PubMed] [Google Scholar]
32. Kho KA, Shields JK. Diagnosis and management of primary dysmenorrhea. *JAMA*. 2020;323:268–9. Doi: 10.1001/jama.2019.16921. [DOI] [PubMed] [Google Scholar]
33. Osayande AS, Mehulic S. Diagnosis and initial management of dysmenorrhea. *Am Fam Physician*. 2014;89:341–6. [PubMed] [Google Scholar]
34. Calis KA, Dang DK, Kalantaridou SN, Erogul M. New York (NY): Medscape; 2019. Dysmenorrhea: practice essentials, background, pathophysiology [Internet] [cited 2021 Mar 8]. Available from:



- <https://emedicine.medscape.com/article/253812-overview>. [Google Scholar]
35. Katz JN, Smith SR, Collins JE, Solomon DH, Jordan JM, Hunter DJ, et al. Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. *Osteoarthritis Cartilage*. 2016;24:409–18. Doi: 10.1016/j.joca.2015.10.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
36. Lazzaroni M, Bianchi Porro G. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. *Aliment Pharmacol Ther*. 2004;20 Suppl 2:48–58. Doi: 10.1111/j.1365-2036.2004.02037.x. [DOI] [PubMed] [Google Scholar]
37. Mendiratta V, Lentz GM. In: *Comprehensive gynecology*. 7th ed. Lobo RA, Gershenson DM, Lentz GM, editors. Philadelphia (PA): Elsevier Inc; 2017. Primary and secondary dysmenorrhea, premenstrual syndrome, and premenstrual dysphoric disorder; pp. 815–28. [Google Scholar]
38. Duggan KC, Walters MJ, Musee J, Harp JM, Kiefer JR, Oates JA, et al. Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. *J Biol Chem*. 2010;285:34950–9. Doi: 10.1074/jbc.M110.162982. [DOI] [PMC free article] [PubMed] [Google Scholar]
39. Harel Z. Dysmenorrhea in adolescents and young adults: an update on pharmacological treatments and management strategies. *Expert Opin Pharmacother*. 2012;13:2157–70. Doi: 10.1517/14656566.2012.725045. [DOI] [PubMed] [Google Scholar]
40. Ryan SA. The treatment of dysmenorrhea. *Pediatr Clin North Am*. 2017;64:331–42. Doi: 10.1016/j.pcl.2016.11.004. [DOI] [PubMed] [Google Scholar]
41. Lefebvre G, Pinsonneault O, Antao V, Black A, Burnett M, Feldman K, et al. Primary dysmenorrhea consensus guideline. *J Obstet Gynaecol Can*. 2005;27:1117–46. Doi: 10.1016/s1701-2163(16)30395-4. [DOI] [PubMed] [Google Scholar]
42. Hinz B, Brune K. Paracetamol and cyclooxygenase inhibition: is there a cause for concern? *Ann Rheum Dis*. 2012;71:20–5. Doi: 10.1136/ard.2011.200087. [DOI] [PubMed] [Google Scholar]
43. Sharghi M, Mansurkhani SM, Larky DA, Kooti W, Niksefat M, Firoozbakht M, et al. An update and systematic review on the treatment of primary dysmenorrhea. *JBRA Assist Reprod*. 2019;23:51–7. Doi: 10.5935/1518-0557.20180083. [DOI] [PMC free article] [PubMed] [Google Scholar]
44. Dawood MY, Khan-Dawood FS. Clinical efficacy and differential inhibition of menstrual fluid prostaglandin F2alpha in a randomized, double-blind, crossover treatment with placebo, acetaminophen, and ibuprofen in primary dysmenorrhea. *Am J Obstet Gynecol*. 2007;196:35.e1–5. Doi: 10.1016/j.ajog.2006.06.091. [DOI] [PubMed] [Google Scholar]
45. Chen CX, Carpenter JS, LaPradd M, Ofner S, Fortenberry JD. Perceived ineffectiveness of pharmacological treatments for dysmenorrhea. *J Womens Health (Larchmt)* 2021;30:1334–43. Doi: 10.1089/jwh.2020.8581. [DOI] [PMC free article] [PubMed] [Google Scholar]
46. Armour M, Parry K, Al-Dabbas MA, Curry C, Holmes K, MacMillan F, et al. Self-care strategies and sources of knowledge on menstruation in 12,526 young women with dysmenorrhea: a systematic review and meta-analysis. *PLoS One*. 2019;14:e0220103. Doi: 10.1371/journal.pone.0220103. [DOI] [PMC free article] [PubMed] [Google Scholar]



47. Armour M, Smith CA, Steel KA, Macmillan F. The effectiveness of self-care and lifestyle interventions in primary dysmenorrhea: a systematic review and meta-analysis. *BMC Complement Altern Med.* 2019;19:22. Doi: 10.1186/s12906-019-2433-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
48. Nie W, Xu P, Hao C, Chen Y, Yin Y, Wang L. Efficacy and safety of over-the-counter analgesics for primary dysmenorrhea: a network meta-analysis. *Medicine (Baltimore)* 2020;99:e19881. Doi: 10.1097/MD.00000000000019881. [DOI] [PMC free article] [PubMed] [Google Scholar]
49. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. *Obstet Gynecol.* 2006;108:428–41. Doi: 10.1097/01.AOG.0000230214.26638.0c. [DOI] [PubMed] [Google Scholar]
50. Daley AJ. Exercise and primary dysmenorrhoea: a comprehensive and critical review of the literature. *Sports Med.* 2008;38:659–70. Doi: 10.2165/00007256-200838080-00004. [DOI] [PubMed] [Google Scholar]
51. Jo J, Lee SH. Heat therapy for primary dysmenorrhea: a systematic review and meta-analysis of its effects on pain relief and quality of life. *Sci Rep.* 2018;8:16252. Doi: 10.1038/s41598-018-34303-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
52. Subasinghe AK, Happo L, Jayasinghe YL, Garland SM, Gorelik A, Wark JD. Prevalence and severity of dysmenorrhoea, and management options reported by young Australian women. *Aust Fam Physician.* 2016;45:829–34. [PubMed] [Google Scholar]
53. Jung JK, Byun JS, Choi JK. Basic understanding of transcutaneous electrical nerve stimulation. *J Oral Med Pain.* 2016;41:145–54. [Google Scholar]
54. Peng WW, Tang ZY, Zhang FR, Li H, Kong YZ, Iannetti GD, et al. Neurobiological mechanisms of TENS-induced analgesia. *Neuroimage.* 2019;195:396–408. Doi: 10.1016/j.neuroimage.2019.03.077. [DOI] [PMC free article] [PubMed] [Google Scholar]
55. Johnson M. Transcutaneous electrical nerve stimulation: mechanisms, clinical application and evidence. *Rev Pain.* 2007;1:7–11. Doi: 10.1177/204946370700100103. [DOI] [PMC free article] [PubMed] [Google Scholar]
56. Parra-Fernandez ML, Onieva-Zafra MD, Abreu-Sanchez A, Ramos-Pichardo JD, Iglesias-Lopez MT, Fernandez-Martinez E. Management of primary dysmenorrhea among university students in the south of Spain and family influence. *Int J Environ Res Public Health.* 2020;17:5570. Doi: 10.3390/ijerph17155570. [DOI] [PMC free article] [PubMed] [Google Scholar]
57. Proctor ML, Latthe PM, Farquhar CM, Khan KS, Johnson NP. Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea. *Cochrane Database Syst Rev.* 2005;(4):CD001896. Doi: 10.1002/14651858.CD001896.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
58. Berner E, Qvigstad E, Myrvold AK, Lieng M. Pain reduction after total laparoscopic hysterectomy and laparoscopic supracervical hysterectomy among women with dysmenorrhoea: a randomised controlled trial. *BJOG.* 2015;122:1102–11. Doi: 10.1111/1471-0528.13362. [DOI] [PubMed] [Google Scholar]
59. Itani, R., Soubra, L., Karout, S., Rahme, D., Karout, L., & Khojah, H. M. (2022). Primary dysmenorrhea: pathophysiology, diagnosis, and treatment updates. *Korean journal of family medicine*, 43(2), 101.
60. Figure no:4
<https://share.google/epnhsK73ESNXBWZDF>



61. Daily JW, Zhang X, Kim DS, Park S. Efficacy of ginger for alleviating the symptoms of primary dysmenorrhea: a systematic review and meta-analysis of randomized clinical trials. *Pain Med.* 2015;16(12):2243-55. Doi:10.1111/pme.12853
62. Chen CX, Barrett B, Kwekkeboom KL. Efficacy of oral ginger (*Zingiber officinale*) for dysmenorrhea: a systematic review and meta-analysis. *Evid Based Complement Alternat Med.* 2016;2016:6295737. doi:10.1155/2016/6295737
63. Lee HW, Ang L, Lee MS, Alimoradi Z, Kim E. Fennel for Reducing Pain in Primary Dysmenorrhea: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Nutrients.* 2020 Nov 10;12(11):3438. doi: 10.3390/nu12113438
64. Khalesi ZB, Beiranvand SP, Bokaie M. Efficacy of chamomile in the treatment of premenstrual syndrome: a systematic review. *J Pharmacopuncture.* 2019;22(4):204-9. doi:10.3831/KPI.2019.22.028
65. Maia H Jr, Haddad C, Casoy J. The effect of Pycnogenol on patients with dysmenorrhea using low-dose oral contraceptives. *Int J Womens Health.* 2014;6:1019–22. Doi:10.2147/IJWH.S75389
66. Robertson NU, Schoonees A, Brand A, Visser J. Pine bark (*Pinus* spp.) extract for treating chronic disorders. *Cochrane Database System Rev.* 2020;9:CD008294. Doi:10.1002/14651858.CD008294.pub5
67. Jahangirifar M, Taebi M, Dolatian M. The effect of Cinnamon on primary dysmenorrhea: A randomized, double-blind clinical trial. *Complement Ther Clin Pract.* 2018 Nov;33:56-60. Doi: 10.1016/j.ctcp.2018.08.001
68. Jaafarpour M, Hatefi M, Najafi F, Khajavikhan J, Khani A. The effect of cinnamon on menstrual bleeding and systemic symptoms with primary dysmenorrhea. *Iran Red Crescent Med J.* 2015 Apr 22;17(4):e27032. Doi: 10.5812/ircmj.17(4)2015.27032
69. Masoumi SZ, Asl HR, Poorolajal J, Panah MH, Oliaei SR. Evaluation of mint efficacy regarding dysmenorrhea in comparison with mefenamic acid: A double blinded randomized crossover study. *Iran J Nurs Midwifery Res.* 2016 Jul-Aug;21(4):363-7. Doi: 10.4103/1735-9066.185574
70. Chumpitazi BP, Kearns GL, Shulman RJ. Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders. *Aliment Pharmacol Ther.* 2018 Mar;47(6):738-752. doi: 10.1111/a
71. Figure no:5
<https://share.google/YKDnsfeHClcIHKHeY>
72. Figure no:6
<https://share.google/y7ldxsyrxuLHOONpT>
73. Figure no:7
<https://share.google/NmWvqKvFA6tFN7oAL>
74. Figure no:8
<https://share.google/N36y7ATR6UgGGKnRV>
75. Figure no:9
<https://share.google/Apt8crXW6xU8M6c9x>
76. Figure no:10
<https://share.google/Pos9ku6kkcppTgDRs>
77. Smorgick N, As-Sanie S. Pelvic Pain in Adolescents. *Semin Reprod Med.* 2018 Mar;36(2):116-122. [PubMed] [Reference list]
78. Marin L, Andrisani A, Buzzaccarini G, Capobianco G, Dessole F, Chiantera V, Laganà AS, Ambrosini G. Membranous dysmenorrhoea in a woman undergoing hormone replacement preparation for embryo transfer – a peculiar case. *Prz Menopauzalny.* 2023 Mar;22(1):55-57. [PMC free article] [PubMed] [Reference list]
79. Habibi N, Huang MS, Gan WY, Zulida R, Safavi SM. Prevalence of Primary

- Dysmenorrhea and Factors Associated with Its Intensity Among Undergraduate Students: A Cross-Sectional Study. *Pain Manag Nurs*. 2015 Dec;16(6):855-61. [PubMed] [Reference list]
80. Femi-Agboola DM, Sekoni OO, Goodman OO. Dysmenorrhea and Its Effects on School Absenteeism and School Activities among Adolescents in Selected Secondary Schools in Ibadan, Nigeria. *Niger Med J*. 2017 Jul-Aug;58(4):143-148. [PMC free article] [PubMed] [Reference list]
 81. .Bajalan Z, Alimoradi Z, Moafi F. Nutrition as a Potential Factor of Primary Dysmenorrhea: A Systematic Review of Observational Studies. *Gynecol Obstet Invest*. 2019;84(3):209-224. [PubMed] [Reference list]
 82. Barnard ND, Scialli AR, Hurlock D, Bertron P. Diet and sex-hormone binding globulin, dysmenorrhea, and premenstrual symptoms. *Obstet Gynecol*. 2000 Feb;95(2):245-50. [PubMed] [Reference list]
 83. Ziaei S, Zakeri M, Kazemnejad A. A randomised controlled trial of vitamin E in the treatment of primary dysmenorrhoea. *BJOG*. 2005 Apr;112(4):466-9. [PubMed] [Reference list]
 84. Proctor ML, Murphy PA. Herbal and dietary therapies for primary and secondary dysmenorrhoea. *Cochrane Database Syst Rev*. 2001;(3):CD002124. [PubMed] [Reference list]
 85. Nagy, H., Carlson, K., & Khan, M. A. (2023). Dysmenorrhea. In *StatPearls* [Internet]. StatPearls Publishing.
 86. Thomas, B., & Magos, A. (2009). Modern management of dysmenorrhoea. *Trends in Urology, Gynaecology & Sexual Health*, 14(5), 25-29.
 87. Durain D. Primary dysmenorrhea: assessment and management update. *J Midwifery Womens Health*. 2004 Nov-Dec. 49(6):520-8. [QxMD MEDLINE Link].
 88. Proctor ML, Murphy PA, Pattison HM, Suckling J, Farquhar CM. Behavioural interventions for primary and secondary dysmenorrhoea. *Cochrane Database Syst Rev*. 2007 Jul 18. CD002248. [QxMD MEDLINE Link]
 89. Latthe P, Mignini L, Gray R, Hills R, Khan K. Factors predisposing women to chronic pelvic pain: systematic review. *BMJ*. 2006 Apr 1. 332(7544):749-55. [QxMD MEDLINE Link]. [Full Text]
 90. Matthewman G, Lee A, Kaur JG, Daley AJ. Physical activity for primary dysmenorrhea: a systematic review and meta-analysis of randomized controlled trials. *Am J Obstet Gynecol*. 2018 Sep. 219 (3):255.e1-255.e20. [QxMD MEDLINE Link].
 91. Tsai IC, Hsu CW, Chang CH, Lei WT, Tseng PT, Chang KV. Comparative Effectiveness of Different Exercises for Reducing Pain Intensity in Primary Dysmenorrhea: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. *Sports Med Open*. 2024 May 30. 10 (1):63. [QxMD MEDLINE Link]. [Full Text].

HOW TO CITE: Harshada Dhak, Prerana Vairag*, Dr. Sonali Uppalwar, A Comparative Study of Herbal Vs Conventional Therapies in Dysmenorrhoea Management, *Int. J. of Pharm. Sci.*, 2025, Vol 3, Issue 11, 2561-2580 <https://doi.org/10.5281/zenodo.17637625>

